• About
  • Licensing
  • Podcasting
  • Contact

AudioMedica.com

Medical News Interviews

  • Public Health
  • Oncology
  • Cardiovascular
  • General Medicine

Audio Journal of Hematologic Malignancy, Volume 2 Number 1

0
  • by alexperjescuadmin
  • in General Medicine
  • — 8 Jan, 2006

Reporting from:
American Society of Hematology Meeting,
Philadelphia, December 6-10, 2002


Scientific Editors:

George Canellos, Dana-Farber Cancer Institute, Boston
Anton Hagenbeek, University of Utrecht
John Goldman, Hammersmith Hospital
Volker Diehl, University of Cologne

Producer:
Derek Thorne
Presenters: Derek Thorne & Peter Goodwin

Interviews in this edition:

Proteasome Inhibitor – New Hope for Refractory Myeloma

Paul Richardson, Dana-Farber Cancer Institute, Boston

The conference heard about a phase II trial of the proteasome inhibitor bortezomib. The drug has shown promising results in a group of heavily pre-treated myeloma patients, without excess toxicity.

COMMENT: George Canellos, Dana-Farber Cancer Institute

Fludarabine, Mitoxantrone, Rituximab Remissions in Mantle Cell Lymphoma

Alexandra Levine, USC Norris Cancer Hospital, Los Angeles

With transplants an unlikely option for older patients with mantle cell lymphoma, what else can a doctor do? This study, involving 15 patients, shows that a triple therapy regimen could produce durable responses

COMMENT: George Canellos, Dana-Farber Cancer Institute

Rituximab to Aid Molecular Lymphoma Remission After Transplant?

Wolfram Brugger, University of Tübingen

Although monoclonal antibodies may not be able to eliminate large numbers of lymphoma cells, they could help to mop up the smaller numbers remaining after more drastic cyto-reductive treatments. Rituximab was tested in this way, in follicular and mantle cell lymphoma.

Immunoconjugate Safe So Far in B-Cell Lymphomas

Myron Czuczman, Roswell Park Cancer Institute, Buffalo

Ibritumomab tiuxetan (zevalin), a radiolabelled monoclonal antibody, is currently in use for the treatment of B-cell lymphomas. But some doctors are concerned that it might promote secondary malignancies. ASH delegates heard about its 9 year safety record.

CD22 Monoclonal to Improve B-Cell NHL Responses?

John Leonard, Cornell University, New York

Epratuzumab is a new monoclonal antibody that recognizes the CD22 antigen on malignant cells. This investigation looked at its performance in patients with B-cell non-Hodgkin’s Lymphoma.

Rituximab Responders: Re-Treatment Best in Relapse

Bertrand Coiffier, Hospices Civils de Lyon

What are the options for non-Hodgkin’s Lymphoma patients who respond to rituximab, but eventually relapse? One retrospective analysis suggests the best option is to use rituximab again.

CML: Imatinib Ahead at Molecular Level

Jerry Radich, Fred Hutchinson Cancer Research Centre, Seattle

The IRIS study is the largest and longest randomized study to compare imatinib with interferon and Ara-C. Molecular response data were presented at ASH.

Optimum Imatinib Dose in Accelerated Phase CML

Richard Silver, New York Presbyterian Hospital, New York

The Philadelphia conference heard about imatinib’s performance in accelerated phase CML. The drug’s general activity in these patients has been known for over a year, and new 3 year results can now help doctors to decide on the best dose.

Decitabine Hope for Imatinib Resistance

Jorge Cortes, MD Anderson Cancer Center, Houston

Because of imatinib resistance, additional drugs for CML are currently on the clinical agenda. One is decitabine, an agent that suppresses the methylation of DNA. This drug was recently tested in patients already treated with imatinib.

Immuno Conjugate Potential for AML

Eric Sievers, Fred Hutchinson Cancer Research Center, Seattle

Gemtuzumab ozogamicin (mylotarg), is a new immuno conjugate for AML. According to the most recent studies, it may perform well both alone and in combination with other treatments.

COMMENT: George Canellos, Dana-Farber Cancer Institute

Gene Guided Therapy Soon for Leukemia

Torsten Haferlach, Ludwig-Maximilians University, Munich

Gene profiling, a technique that identifies abnormally expressed genes in malignant cells, may provide accurate and rapid diagnosis of leukemias within a few years, according to a number of investigations presented at ASH.

COMMENT: George Canellos, Dana-Farber Cancer Institute

Share

You may also like...

  • Audio Journal of Medicine – July 20th Audio Journal of Medicine – July 20th 20 Jul, 2006
  • News from the 23rd Annual Meeting of the European Society of Human Reproduction and Embryology, Lyon, July 1-4, 2007 News from the 23rd Annual Meeting of the European Society of Human Reproduction and Embryology, Lyon, July 1-4, 2007 3 Jul, 2007
  • Audio Journal of Hematologic Malignancy Special Edition 2005 Audio Journal of Hematologic Malignancy Special Edition 2005 14 Jan, 2006
  • Gene Study Identifies Heart Disease Risk Gene Study Identifies Heart Disease Risk 29 Aug, 2007

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

  • Previous story Subscribe to Audio Medica’s podcast coverage from the 45th Annual ICAAC – Interscience Conference on Antimicrobial Agents and Chemotherapy.
  • Next story Hematologic Malignancy
  • News

    • Mandeep Mehra MDCOVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
    • Ultrahypofractionated Radiation Just As Effective for Prostate CancerUltrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
  • Related interviews

    • Ibrutinib: New Frontline Standard for Chronic…
    • New Front Line Standard for Older Patients with…
    • Microbiome Diversity Key To Survival After…
    • Trifluridine with Tipiracil Lifts Survival in…
    • Genomic-led AML Clinical Decision Making Within Seven Days
  • Home
  • General Medicine
  • Audio Journal of Hematologic Malignancy, Volume 2 Number 1

© Copyright 2021 AudioMedica.com. Typegrid Theme by WPBandit.